|
|
|
|
|
11.12.25 - 23:27
|
Cycle Pharmaceuticals to Acquire Applied Therapeutics (GlobeNewswire EN)
|
|
|
Applied Therapeutic's lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases Applied Therapeutic's lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases...
|
|
|
|
|
|
|
|
|
29.09.25 - 13:03
|
Applied Therapeutics Provides Update Following Meeting with FDA (GlobeNewswire EN)
|
|
|
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the Company), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today announced that the Company completed a meeting with the U.S. Food and Drug Administration (FDA) to discuss the potential new drug application (NDA) submission for govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase (SORD) Deficiency (CMT-SORD) in the third quarter of 2025....
|
|
|
|
|
|
|
|
|
17.06.25 - 22:06
|
Applied Therapeutics Announces Key Leadership Appointments (GlobeNewswire EN)
|
|
|
NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced key appointments to its executive leadership team with the promotions of Evan Bailey, MD, to Chief Medical Officer (CMO), effective June 15, 2025, and Dottie Caplan to Executive Vice President (EVP), Patient Advocacy and Government Affairs....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.03.25 - 13:15
|
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission (GlobeNewswire EN)
|
|
|
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission (“SEC”) related to the Company's Annual Report on Form 10-K for the fiscal year 2024 (the “Form 10-K”). Form 12b-25 will allow the Company an automatic extension of 15 additional calendar days to file the Form 10-K for the fiscal year 2024, which is due on March 31, 2025. The Company is working diligently to finalize its financial statements and currently expects to file its Annual Report on Form 10-K as soon as practicable by April 15, 2025, the end of the 15-day extension period, in accordance with Rule 12b-25....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
